← Back to Search

CAR T-cell Therapy

CRISPR CAR-T Cell Therapy for B-Cell Lymphoma

Phase 1
Recruiting
Research Sponsored by Caribou Biosciences, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Documented diagnosis of relapsed or refractory non-Hodgkin lymphoma after prior standard of care
Age greater than or equal to 18 at the time of enrollment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights

Study Summary

This trial is studying a new drug, CB-010, to see if it is safe and effective in treating adults with B cell non-Hodgkin lymphoma that has come back or does not respond to other treatment.

Who is the study for?
Adults over 18 with relapsed/refractory B cell non-Hodgkin lymphoma who've had standard treatments can join. They must be fairly healthy, able to perform daily activities (ECOG status 0 or 1), and have good organ function. Excluded are those needing steroids, with certain neurological or autoimmune diseases, previous anti-CD19 therapy, stem cell transplants, CNS lymphoma/malignancy, primary immunodeficiency, active thyroid disorders (except stable hypothyroidism), and other recent cancers.Check my eligibility
What is being tested?
The ANTLER trial is testing CB-010 after a pre-treatment ('lymphodepletion') with fludarabine and cyclophosphamide in adults with advanced B cell non-Hodgkin lymphoma. It aims to assess the safety of this CRISPR-edited CAR-T therapy as well as its potential effectiveness and how the body processes it.See study design
What are the potential side effects?
Possible side effects include reactions related to immune system activation such as fever and fatigue (cytokine release syndrome), blood abnormalities, infections due to low blood counts from chemotherapy pre-treatment, allergic reactions during infusion of the CAR-T cells, and organ inflammation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My non-Hodgkin lymphoma has returned or didn't respond after standard treatment.
Select...
I am 18 years old or older.
Select...
I am fully active or can carry out light work.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
evaluates tumor response (Part B)
measures number of patients with dose-limiting toxicities (Part A).

Trial Design

2Treatment groups
Experimental Treatment
Group I: Expansion of CB-010Experimental Treatment3 Interventions
Patients with relapsed or refractory non-Hodgkin lymphoma will receive CB-010 following lymphodepletion.
Group II: Dose Escalation of CB-010Experimental Treatment3 Interventions
Patients with relapsed or refractory non-Hodgkin lymphoma will receive CB-010 following lymphodepletion.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide
1995
Completed Phase 3
~3770
Fludarabine
2012
Completed Phase 3
~1100

Find a Location

Who is running the clinical trial?

Caribou Biosciences, Inc.Lead Sponsor
3 Previous Clinical Trials
220 Total Patients Enrolled
1 Trials studying Lymphoma
100 Patients Enrolled for Lymphoma

Media Library

CB-010 (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04637763 — Phase 1
Lymphoma Research Study Groups: Dose Escalation of CB-010, Expansion of CB-010
Lymphoma Clinical Trial 2023: CB-010 Highlights & Side Effects. Trial Name: NCT04637763 — Phase 1
CB-010 (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04637763 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any possible risks associated with taking CB-010?

"Considering that only initial trials have been conducted on CB-010, our team at Power has placed it with a safety rating of 1."

Answered by AI

How many health care settings are executing this experiment?

"At the moment, this investigation is being conducted at 9 medical centres scattered across Dallas, La Jolla and Houston among other cities. To decrease travel demands it's best to select a study site close by when signing up for participation."

Answered by AI

Is recruitment for this clinical trial still ongoing?

"This clinical experiment is actively seeking participants at the moment, as indicated on clinicaltrials.gov. It was initially advertised on May 26th 2021 and most recently updated in October 31st 2022."

Answered by AI

Could you provide an overview of any prior experiments involving CB-010?

"CB-010 was first explored by the City of Hope Comprehensive Cancer Center in 1997 and since then, there have been 1275 completed studies. Currently 889 clinical trials are looking for participants with a sizeable amount located in Dallas, Texas."

Answered by AI

How many participants are encompassed by this research project?

"A total of 50 suitable participants must be sourced in order to execute the trial. Caribou Biosciences, Inc., will conduct this research at various sites including Baylor Charles A. Sammons Cancer Center and University of California San Diego Moores Cancer Center."

Answered by AI

What ailments does CB-010 commonly treat?

"CB-010 is predominantly used for multiple sclerosis, but has been known to also be effective in treating mixed cell type lymphoma, leukemia, myelocytic disease, acute forms of the same and retinoblastoma."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
2021. "CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04637763.
~22 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top